Lumida
/CRSP
⌘K
CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSP
$51.72USD-1.03%-0.54 today

MARKET CAP

5.0B

P/E (TTM)

FWD P/E

DAY RANGE

$52 – $53

52W RANGE

$44
$78

AI Summary

Stalk
Sell NowMedium

CRSP has broken decisively below its key horizontal support zone and 9/20 EMAs, confirming a medium-term bearish phase. Short-term momentum remains negative with price extended below EMAs and no signs of exhaustion. We will execute Sell Now on continued weakness, viewing any rally into the broken support zone as an opportunity to reinforce positions to the downside.

  • Q2 CASGEVY sales $76M (+151% YoY) drives strong growth.
  • Q2 revenue $10.2M vs $7M consensus; beat expectations.
  • Q2 loss of $0.94/sh vs $1.10 estimate highlights ongoing deficits.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$915.0M$1.2M$371.2M$37.3M$3.5M
YoY %+127154.9%-99.9%+30885.5%-89.9%-90.6%
P / Sales6.7x2660.8x14.1x89.0x1343.5x
EV / Sales6.0x2790.7x14.0x89.3x1342.3x
Gross Profit, Adj.$915.0M$1.2M$371.2M$37.3M$3.5M
YoY %+127154.9%-99.9%+30885.5%-89.9%-90.6%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit6.0x2790.7x14.0x89.3x1342.3x
EBITDA, Adj.$391.5M$-649.0M$-202.7M$-447.3M$-645.1M
YoY %+213.4%-265.8%+68.8%-120.7%-44.2%
Margin %42.8%-54172.7%-54.6%-1198.8%-18378.7%
EV / EBITDA14.1x-5.2x-25.6x-7.4x-7.3x
EBIT$373.5M$-673.2M$-222.5M$-466.6M$-664.6M
YoY %+205.4%-280.2%+66.9%-109.7%-42.4%
Margin %40.8%-56190.4%-60.0%-1250.4%-18933.6%
EV / EBIT14.8x-5.0x-23.3x-7.1x-7.1x
Net Income$377.7M$-650.2M$-153.6M$-366.3M$-581.6M
YoY %+208.3%-272.2%+76.4%-138.4%-58.8%
Net Margin41.3%-54271.7%-41.4%-981.5%-16569.8%
EPS (GAAP)$4.70-$8.36-$1.94-$4.34-$6.47
YoY %+188.8%-277.9%+76.8%-123.7%-49.1%